Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. - Test2 - elhamkhani - TriplyDB

Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

http://www.wikidata.org/entity/Q38797637

about

Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer.HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity.Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells Stepwise assembly of functional C-terminal REST/NRSF transcriptional repressor complexes as a drug target.Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.4SC-202 as a Potential Treatment for the Pediatric Brain Tumor Medulloblastoma.Targeting PP2A activates AMPK signaling to inhibit colorectal cancer cells.

P2860

Q28822336-C9F22A94-E288-42DC-901B-BA4FA17E48B4 Q30489412-0D5D6A23-C2A0-4E9D-81BF-40EA15624EB5 Q33821384-107B6E91-5BB7-4A32-8F25-F83AD777EDBA Q37607905-A69D933A-389E-4637-8FEB-4BE15498094B Q37684405-1A3167D0-7E80-46FA-87F0-DED8C69243F6 Q37716430-9C55A5AA-DC37-4AF9-A2C6-2571BBA703CA Q37718446-929413B0-E86D-41A7-AE7E-11BCBC641387 Q41987823-A8C645D6-BB6A-43C7-9A57-C701C6E9E67A Q47096044-B2CA7B7B-124F-4806-A124-395EAD2BC869 Q47116612-CD2CA6FE-0648-4622-A456-9CC249C6AADE Q47130471-34F8A904-A467-4EDC-B899-45F88C93DB9E

P2860

Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

http://www.wikidata.org/entity/Q38797637

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pre-clinical characterization ...... ainst colorectal cancer cells.

@en

type

label

Pre-clinical characterization ...... ainst colorectal cancer cells.

@en

prefLabel

Pre-clinical characterization ...... ainst colorectal cancer cells.

@en

P1433

Q38797637-12D0B4EB-896C-4DEF-ADAD-5A2876E39D8B

P1476

Q38797637-7C4E53E6-1741-4CA5-B1A6-DAEB265F2407

P2093

Q38797637-06CD986C-FCF7-4D26-A87F-D76B5C293FFF

Q38797637-3325498E-0526-4603-9026-474694CF8152

Q38797637-72DC84B9-4B54-4AD1-8903-665BE9949829

Q38797637-7AA08269-02CB-49DE-BB75-38C24A1507D6

Q38797637-BB3C8FD7-B77F-4E9A-B245-9E7EBFA249FF

Q38797637-D978EE01-AF3F-41CD-ACFC-F4EBB71BFB5A

P2860

Q38797637-09F1CEC3-1CAE-4F44-AC61-16B9387E57A7

Q38797637-10068C6B-824B-49B0-A8DC-D5C1758AB227

Q38797637-12EB1DB9-5FA9-4227-BA9F-73160627115A

Q38797637-13EF622A-40E7-460F-8D04-1631357903F5

Q38797637-231C6F22-4906-4E75-9BBC-6568C40E83ED

Q38797637-2B964885-3DE6-49E4-AB42-EBADC0996746

Q38797637-2BDE5BDE-C619-4636-A56D-6BB28DAC4542

Q38797637-3091925F-8BEB-4796-8297-94017DF0D224

Q38797637-31B06102-6708-4EC3-ACCA-F6EAB8AE6166

Q38797637-34D3772B-7074-4B22-8DFD-A4692E3514EC

P2888

Q38797637-950C8911-15B9-4E94-90A6-EFC204B72A7E

P304

Q38797637-89624EAE-6795-4617-BF59-EBA87D5E2658

P31

Q38797637-5E165848-0652-4F1D-8E3E-031F269BD5FF

P356

Q38797637-E28C0EE3-69D9-42B0-A4E2-5D64156BA128

P433

Q38797637-D26E03CC-AF52-4F91-95C0-BFF4A8A8B758

P478

Q38797637-286910CA-070F-4833-9C31-14DC7708E419

P577

Q38797637-B8831B8E-BC25-4697-94D2-1EF3FD458AB7

P6179

Q38797637-DB2564B5-C70C-4921-8C22-6331BE531D00

P698

Q38797637-086BE1CC-D3F6-47E8-850E-CC56769D6CC7

P921

Q38797637-4592F63D-3CAC-4517-966B-7A5518AFC819

P356

S13277-016-4868-6

P1433

P1476

Pre-clinical characterization ...... ainst colorectal cancer cells.

@en

P2093

Huang Zhijun

http://www.w3.org/2001/XMLSchema#string

Li Dechun

http://www.w3.org/2001/XMLSchema#string

Li Jianping

http://www.w3.org/2001/XMLSchema#string

Min Han

http://www.w3.org/2001/XMLSchema#string

Qin Li-Sen

http://www.w3.org/2001/XMLSchema#string

Wang Shusheng

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

XAV939: from a small inhibitor to a potent drug bioconjugate when delivered by gold nanoparticles

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.

Histone deacetylases and cancer: causes and therapies.

C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo.

ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis

The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer

Adjuvant therapy of colon cancer: current status and future directions.

P2888

s13277-016-4868-6

P304

10257-10267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-016-4868-6

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023938929

http://www.w3.org/2001/XMLSchema#string

P698

26831668

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer